Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 169
Filter
1.
Vitam Horm ; 102: 101-19, 2016.
Article in English | MEDLINE | ID: mdl-27450732

ABSTRACT

Thymosinα1 is a peptidic hormone with pleiotropic activity, which is used in the therapy of several diseases. It is unstructured in water solution and interacts with negative regions of micelles and vesicles assuming two tracts of helical conformation with a structural flexible break in between. The studies of the interaction of Thymosinα1 with micelles of mixed dipalmitoylphosphatidylcholine and sodium dodecylsulfate and vesicles with mixed dipalmitoylphosphatidylcholine/dipalmitoylphosphatidylserine, the latter the negative component of the membranes, by (1)H and natural abundance (15)N NMR are herewith reported, reviewed, and discussed. The results indicate that the preferred interactions are those where the surface is negatively charged due to sodium dodecylsulfate or due to the presence of dipalmitoylphosphatidylserine exposed on the surface. In fact the unbalance of dipalmitoylphosphatidylserine on the cellular surface is an important phenomenon present in pathological conditions of cells. Moreover, the direct interaction of Thymosinα1 with K562 cells presenting an overexposure of phosphatidylserine as a consequence of resveratrol-induced apoptosis was carried out.


Subject(s)
Cell Membrane/chemistry , Phosphatidylserines/chemistry , Thymosin/analogs & derivatives , Amino Acid Sequence , Cell Membrane/metabolism , Circular Dichroism , Deuterium , Humans , Magnetic Resonance Spectroscopy , Micelles , Models, Molecular , Molecular Structure , Protein Binding , Protein Conformation , Solutions , Thymalfasin , Thymosin/chemistry , Thymosin/metabolism , Trifluoroethanol
2.
Clin Exp Immunol ; 186(1): 39-45, 2016 10.
Article in English | MEDLINE | ID: mdl-27350088

ABSTRACT

Thymosin alpha 1 (Tα1) is a powerful modulator of immunity and inflammation. Despite years of studies, there are a few reports evaluating serum Tα1 in health and disease. We studied a cohort of healthy individuals in comparison with patients affected by chronic inflammatory autoimmune diseases. Sera from 120 blood donors (healthy controls, HC), 120 patients with psoriatic arthritis (PsA), 40 with rheumatoid arthritis (RA) and 40 with systemic lupus erythematosus (SLE), attending the Transfusion Medicine or the Rheumatology Clinic at the Policlinico Tor Vergata, Rome, Italy, were tested for Tα1 content by means of a commercial enzyme-linked immunosorbent assay (ELISA) kit. Data were analysed in relation to demographic and clinical characteristics of patients and controls. A gender difference was found in the HC group, where females had lower serum Tα1 levels than males (P < 0·0001). Patients had lower serum Tα1 levels than HC (P < 0·0001), the lowest were observed in PsA group (P < 0·0001 versus all the other groups). Among all patients, those who at the time of blood collection were taking disease-modifying anti-rheumatic drugs (DMARD) plus steroids had significantly higher Tα1 levels than those taking DMARD alone (P = 0·044) or no treatment (P < 0·0001), but not of those taking steroids alone (P = 0·280). However, whichever type of treatment was taken by the patients, serum Tα1 was still significantly lower than in HC and there was no treatment-related difference in PsA group. Further prospective studies are necessary to confirm and deepen these observations. They might improve our understanding on the regulatory role of Tα1 in health and disease and increase our knowledge of the pathogenesis of chronic inflammatory autoimmune diseases.


Subject(s)
Autoimmune Diseases/blood , Inflammation/blood , Thymosin/analogs & derivatives , Adult , Aged , Autoimmune Diseases/diagnosis , Autoimmune Diseases/drug therapy , Biomarkers , Case-Control Studies , Chronic Disease , Female , Humans , Inflammation/diagnosis , Inflammation/drug therapy , Male , Middle Aged , Retrospective Studies , Severity of Illness Index , Thymalfasin , Thymosin/blood , Treatment Outcome , Young Adult
3.
Cell Death Dis ; 6: e1622, 2015 Jan 29.
Article in English | MEDLINE | ID: mdl-25633291

ABSTRACT

miR-34a is involved in the regulation of the fate of different cell types. However, the mechanism by which it controls the differentiation programme of neural cells remains largely unknown. Here, we investigated the role of miR-34a in neurogenesis and maturation of developing neurons and identified Doublecortin as a new miR-34a target. We found that the overexpression of miR-34a in vitro significantly increases precursor proliferation and influences morphology and function of developing neurons. Indeed, miR-34a overexpressing neurons showed a decreased expression of several synaptic proteins and receptor subunits, a decrement of NMDA-evoked current density and, interestingly, a more efficient response to synaptic stimulus. In vivo, miR-34a overexpression showed stage-specific effects. In neural progenitors, miR-34a overexpression promoted cell proliferation, in migratory neuroblasts reduced the migration and in differentiating newborn neurons modulated process outgrowth and complexity. Importantly, we found that rats overexpressing miR-34a in the brain have better learning abilities and reduced emotionality.


Subject(s)
Behavior, Animal , Cell Shape , MicroRNAs/metabolism , Neurogenesis , Neurons/cytology , Neurons/metabolism , Animals , Base Sequence , Bromodeoxyuridine/metabolism , Cell Differentiation , Cell Movement , Cell Proliferation , Cells, Cultured , Cerebral Cortex/cytology , Cognition , Dependovirus/metabolism , Doublecortin Domain Proteins , Doublecortin Protein , Emotions , Female , Microtubule-Associated Proteins/genetics , Microtubule-Associated Proteins/metabolism , Mitosis , Molecular Sequence Data , Neuritis/metabolism , Neuropeptides/genetics , Neuropeptides/metabolism , Phenotype , Rats, Wistar , Stem Cells/cytology
4.
Cell Death Dis ; 4: e944, 2013 Dec 05.
Article in English | MEDLINE | ID: mdl-24309931

ABSTRACT

Central memory (T(CM)) and transitional memory (T(TM)) CD4(+) T cells are known to be the major cellular reservoirs for HIV, as these cells can harbor a transcriptionally silent form of viral DNA that is not targeted by either the immune system or current antiretroviral drug regimens. In the present study, we explored the molecular bases of the anti-HIV reservoir effects of auranofin (AF), a pro-oxidant gold-based drug and a candidate compound for a cure of AIDS. We here show that T(CM) and T(TM) lymphocytes have lower baseline antioxidant defenses as compared with their naive counterpart. These differences are mirrored by the effects exerted by AF on T-lymphocytes: AF was able to exert a pro-differentiating and pro-apoptotic effect, which was more pronounced in the memory subsets. AF induced an early activation of the p38 mitogen-activated protein kinase (p38 MAPK) followed by mitochondrial depolarization and a final burst in intracellular peroxides. The pro-differentiating effect was characterized by a downregulation of the CD27 marker expression. Interestingly, AF-induced apoptosis was inhibited by pyruvate, a well-known peroxide scavenger, but pyruvate did not inhibit the pro-differentiating effect of AF, indicating that the pro-apoptotic and pro-differentiating effects involve different pathways. In conclusion, our results demonstrate that AF selectively targets the T(CM)/T(TM) lymphocyte subsets, which encompass the HIV reservoir, by affecting redox-sensitive cell death pathways.


Subject(s)
Auranofin/pharmacology , Lymphocytes/drug effects , Lymphocytes/metabolism , Apoptosis/drug effects , Blotting, Western , CD4-Positive T-Lymphocytes/metabolism , Cell Separation , Cells, Cultured , Glutathione/metabolism , Humans , Oxidative Stress/drug effects , Real-Time Polymerase Chain Reaction , Reverse Transcriptase Polymerase Chain Reaction , Sulfhydryl Compounds/metabolism
5.
Cell Death Dis ; 3: e389, 2012 Sep 06.
Article in English | MEDLINE | ID: mdl-22951986

ABSTRACT

Exploitation of the biologic activity of neurotrophins is desirable for medical purposes, but their protein nature intrinsically bears adverse pharmacokinetic properties. Here, we report synthesis and biologic characterization of a novel class of low molecular weight, non-peptidic compounds with NGF (nerve growth factor)-mimetic properties. MT2, a representative compound, bound to Trk (tropomyosin kinase receptor)A chain on NGF-sensitive cells, as well as in cell-free assays, at nanomolar concentrations and induced TrkA autophosphorylation and receptor-mediated internalization. MT2 binding involved at least two amino-acid residues within TrkA molecule. Like NGF, MT2 increased phosphorylation of extracellular signal-regulated kinase 1/2 and Akt proteins and production of MKP-1 phosphatase (dual specificity phosphatase 1), modulated p38 mitogen-activated protein kinase activation,sustained survival of serum-starved PC12 or RDG cells, and promoted their differentiation. However, the intensity of such responses was heterogenous, as the ability of maintaining survival was equally possessed by NGF and MT2, whereas the induction of differentiation was expressed at definitely lower levels by the mimetic. Analysis of TrkA autophosphorylation patterns induced by MT2 revealed a strong tyrosine (Tyr)490 and a limited Tyr785 and Tyr674/675 activation, findings coherent with the observed functional divarication. Consistently, in an NGF-deprived rat hippocampal neuronal model of Alzheimer Disease, MT2 could correct the biochemical abnormalities and sustain cell survival. Thus, NGF mimetics may reveal interesting investigational tools in neurobiology, as well as promising drug candidates.


Subject(s)
Azepines/pharmacology , Nerve Growth Factor/pharmacology , Receptor, trkA/agonists , Animals , Azepines/chemistry , Binding Sites , Cell Differentiation/drug effects , Cell Line, Tumor , Cell Survival/drug effects , Hippocampus/cytology , Hippocampus/metabolism , Humans , Mice , Mitogen-Activated Protein Kinase 1/metabolism , Mitogen-Activated Protein Kinase 3/metabolism , Molecular Weight , NIH 3T3 Cells , Nerve Growth Factor/genetics , Nerve Growth Factor/metabolism , PC12 Cells , Phosphorylation , Protein Structure, Tertiary , Proto-Oncogene Proteins c-akt/metabolism , Rats , Receptor, trkA/metabolism , Recombinant Proteins/genetics , Recombinant Proteins/metabolism , Recombinant Proteins/pharmacology , p38 Mitogen-Activated Protein Kinases/metabolism
6.
Cell Death Dis ; 3: e339, 2012 07 05.
Article in English | MEDLINE | ID: mdl-22764098

ABSTRACT

Exploitation of the biologic activity of neurotrophins is desirable for medical purposes, but their protein nature intrinsically bears adverse pharmacokinetic properties. Here, we report synthesis and biologic characterization of a novel class of low molecular weight, non-peptidic compounds with NGF (nerve growth factor)-mimetic properties. MT2, a representative compound, bound to Trk (tropomyosin kinase receptor)A chain on NGF-sensitive cells, as well as in cell-free assays, at nanomolar concentrations and induced TrkA autophosphorylation and receptor-mediated internalization. MT2 binding involved at least two amino-acid residues within TrkA molecule. Like NGF, MT2 increased phosphorylation of extracellular signal-regulated kinase1/2 and Akt proteins and production of MKP-1 phosphatase (dual specificity phosphatase 1), modulated p38 mitogen-activated protein kinase activation, sustained survival of serum-starved PC12 or RDG cells, and promoted their differentiation. However, the intensity of such responses was heterogenous, as the ability of maintaining survival was equally possessed by NGF and MT2, whereas the induction of differentiation was expressed at definitely lower levels by the mimetic. Analysis of TrkA autophosphorylation patterns induced by MT2 revealed a strong tyrosine (Tyr)490 and a limited Tyr785 and Tyr674/675 activation, findings coherent with the observed functional divarication. Consistently, in an NGF-deprived rat hippocampal neuronal model of Alzheimer Disease, MT2 could correct the biochemical abnormalities and sustain cell survival. Thus, NGF mimetics may reveal interesting investigational tools in neurobiology, as well as promising drug candidates.


Subject(s)
Azepines/pharmacology , Nerve Growth Factor/pharmacology , Receptor, trkA/agonists , Animals , Azepines/chemistry , Binding Sites , Cell Differentiation/drug effects , Cell Line, Tumor , Cell Survival/drug effects , Hippocampus/cytology , Hippocampus/metabolism , Humans , Mice , Mitogen-Activated Protein Kinase 1/metabolism , Mitogen-Activated Protein Kinase 3/metabolism , Molecular Weight , NIH 3T3 Cells , Nerve Growth Factor/genetics , Nerve Growth Factor/metabolism , PC12 Cells , Phosphorylation , Protein Structure, Tertiary , Proto-Oncogene Proteins c-akt/metabolism , Rats , Receptor, trkA/metabolism , Recombinant Proteins/genetics , Recombinant Proteins/metabolism , Recombinant Proteins/pharmacology , p38 Mitogen-Activated Protein Kinases/metabolism
7.
Cell Death Dis ; 1: e81, 2010 Oct 07.
Article in English | MEDLINE | ID: mdl-21368854

ABSTRACT

In this study, we investigated molecular mechanisms underlying low susceptibility to apoptosis induced by the nucleoside analog azidothymidine (AZT) and the role of nuclear factor-κB (NF-κB) activation in these phenomena. A preliminary screening in different cell lines indicated U937 monocytic cell line as suitable to this purpose. Treatment of U937 cells even with suprapharmacological concentrations of AZT induced only moderate levels of apoptosis. Surprisingly, SuperArray analysis showed that AZT induced the transcriptional activity of both pro- and anti-apoptotic genes. Interestingly, moreover, several genes upregulated by AZT were NF-κB related. In fact, AZT, after an initial inhibition of NF-κB activation with respect to control, induced a transient, but consistent, increase in NF-κB-binding activity. Inhibition of NF-κB activation in U937 cells, stably transfected with a dominant-negative IκBα or by pharmacological treatment, sensitized them to apoptosis induced by AZT and impaired the upregulation of anti-apoptotic genes in response to AZT treatment, with respect to control cells. These results indicate that NF-κB activation by AZT has a role in protecting target cells from apoptotic cell death, improving our understanding of the toxicology and the therapeutic usage of this drug.


Subject(s)
Antimetabolites/pharmacology , Apoptosis , NF-kappa B/metabolism , Zidovudine/pharmacology , Gene Expression Regulation, Neoplastic , Humans , NF-kappa B/antagonists & inhibitors , Oligonucleotide Array Sequence Analysis , U937 Cells
8.
Int J Immunopathol Pharmacol ; 22(2): 263-8, 2009.
Article in English | MEDLINE | ID: mdl-19505379

ABSTRACT

Periodontitis is an inflammatory disease of bacterial origin, characterized by an inconstant progression of lesions affecting the tooth supporting tissues. In spite of more than half a century of research efforts, the clinician still lacks any specific molecular or microbial diagnostic tool to predict the progression of periodontal lesions. Recently, several reports have proposed a role for some herpesviruses in the etiology of destructive phases of periodontitis. This paper critically analyzes these data in the light of consolidated knowledge that was developed in the characterization of virus-bacteria cooperative interactions, and proposes new topics of investigation to clarify the role of herpesviral infections in periodontitis and their potential predictive role as markers of progression.


Subject(s)
Gingiva/virology , Herpesviridae/pathogenicity , Periodontitis/virology , Animals , Disease Progression , Epithelial Cells/virology , Evidence-Based Medicine , Gingiva/immunology , Gingiva/microbiology , Humans , Periodontitis/immunology , Periodontitis/microbiology , Risk Factors
9.
Exp Cell Res ; 315(5): 849-62, 2009 Mar 10.
Article in English | MEDLINE | ID: mdl-19167380

ABSTRACT

Melanoma development is a multi-step process arising from a series of genetic and epigenetic events. Although the sequential stages involved in progression from melanocytes to malignant melanoma are clearly defined, our current understanding of the mechanisms leading to melanoma onset is still incomplete. Growing evidence show that the activation of endogenous retroviral sequences might be involved in transformation of melanocytes as well as in the increased ability of melanoma cells to escape immune surveillance. Here we show that human melanoma cells in vitro undergo a transition from adherent to a more malignant, non-adherent phenotype when exposed to stress conditions. Melanoma-derived non-adherent cells are characterized by an increased proliferative potential and a decreased expression of both HLA class I molecules and Melan-A/MART-1 antigen, similarly to highly malignant cells. These phenotypic and functional modifications are accompanied by the activation of human endogenous retrovirus K expression (HERV-K) and massive production of viral-like particles. Down-regulation of HERV-K expression by RNA interference prevents the transition from the adherent to the non-adherent growth phenotype in low serum. These results implicate HERV-K in at least some critical steps of melanoma progression.


Subject(s)
Cell Transformation, Viral , Endogenous Retroviruses/physiology , Melanoma/virology , Virus Activation/physiology , Caco-2 Cells , Cell Proliferation , Cell Transformation, Viral/genetics , Cells, Cultured , Clone Cells/virology , Disease Progression , Endogenous Retroviruses/genetics , Humans , Jurkat Cells , K562 Cells , Melanocytes/pathology , Melanocytes/ultrastructure , Melanocytes/virology , Melanoma/etiology , Melanoma/genetics , Melanoma/pathology , Models, Biological , RNA, Viral/isolation & purification , Virion/growth & development , Virus Activation/genetics
11.
Curr Med Chem ; 13(15): 1749-55, 2006.
Article in English | MEDLINE | ID: mdl-16787218

ABSTRACT

Reduced glutathione (GSH) is present in millimolar concentrations in mammalian cells. It is involved in many cellular functions such as detoxification, amino acid transport, production of coenzymes, and the recycling of vitamins E and C. GSH acts as a redox buffer to preserve the reduced intracellular environment. Decreased glutathione levels have been found in numerous diseases such as cancer, viral infections, and immune dysfunctions. Many antioxidant molecules, such as GSH and N-acetylcysteine (NAC), have been demonstrated to inhibit in vitro and in vivo viral replication through different mechanisms of action. Accumulating evidence suggests that intracellular GSH levels in antigen-presenting cells such as macrophages, influence the Th1/Th2 cytokine response pattern, and more precisely, GSH depletion inhibits Th1-associated cytokine production and/or favours Th2 associated responses. It is known that GSH is not transported to most cells and tissues in a free form. Therefore, a number of different approaches have been developed in the last years to circumvent this problem. This review discusses the capacity of some new molecules with potent pro-GSH effects either to exert significant antiviral activity or to augment GSH intracellular content in macrophages to generate and maintain the appropriate Th1/Th2 balance. The observations reported herein show that pro-GSH molecules represent new therapeutic agents to treat antiviral infections and Th2-mediated diseases such as allergic disorders and AIDS.


Subject(s)
Adjuvants, Immunologic/pharmacology , Antiviral Agents/pharmacology , Glutathione/pharmacology , Animals , Glutathione/physiology , Humans , Mice , Th1 Cells/immunology , Th2 Cells/immunology , Virus Diseases/physiopathology
12.
J Chemother ; 18(6): 589-602, 2006 Dec.
Article in English | MEDLINE | ID: mdl-17267336

ABSTRACT

The most frequent agents of severe bacterial infections and their antibiotic susceptibility patterns were determined in patients admitted to 45 Italian hospitals over the years 2002-2003. The most common diagnoses were: sepsis (33.8%), pneumonia (9.4%), intravascular catheter-associated infections (9.3%) and ventilator-associated pneumonia (8.1%). Overall, 5115 bacterial isolates were identified from 4228 patients. Three bacterial species, Staphylococcus aureus, Pseudomonas aeruginosa and Escherichia coli, accounted for more than 50% of the isolates. Other prevalent bacterial isolates were Staphylococcus epidermidis and Enterococcus faecalis, while Acinetobacter baumanii ranked third among all Intensive Care Unit (ICU) isolates. 7% of S. aureus had intermediate resistance to vancomycin. Although E. faecalis displayed no vancomycin resistance, 34% of vancomycin-resistant isolates were found among Enterococcus faecium, one of the highest rates found to date, emphasizing the difference between these two enterococcal species. All the Gram-positive pathogens were susceptible to linezolid, with the exception of approximately 2% of the enterococcal isolates that were intermediate with a minimum inhibitory concentration (MIC)=4 microg/ml. Almost 10% of Escherichia coli, 14% of Klebsiella pneumoniae, 22% of Serratia marcescens and 50% of Enterobacter cloacae were non-susceptible to cefotaxime. Amikacin was the most active antibiotic against P. aeruginosa that showed lack of susceptibility to ceftazidime, gentamicin, piperacillin and ciprofloxacin ranging from 20 to 35%. Finally, Acinetobacter baumanii showed a high level of resistance to all the antibiotics tested including imipenem (58%). The results obtained in this study, the first of its kind in Italy, offer indications for guiding empirical therapy and implementing specific interventions to fight antibiotic-resistant bacterial infections and their transmission in the hospital setting in Italy.


Subject(s)
Anti-Bacterial Agents/pharmacology , Bacteria/drug effects , Bacterial Infections/microbiology , Adolescent , Adult , Aged , Aged, 80 and over , Bacteria/isolation & purification , Bacterial Infections/epidemiology , Child , Child, Preschool , Community-Acquired Infections/epidemiology , Community-Acquired Infections/microbiology , Cross Infection/epidemiology , Cross Infection/microbiology , Drug Resistance, Bacterial , Female , Gram-Negative Bacteria/drug effects , Gram-Negative Bacteria/isolation & purification , Gram-Positive Bacteria/drug effects , Gram-Positive Bacteria/isolation & purification , Hospitals/statistics & numerical data , Humans , Infant , Infant, Newborn , Italy/epidemiology , Male , Microbial Sensitivity Tests , Middle Aged
14.
Eur Rev Med Pharmacol Sci ; 8(2): 69-77, 2004.
Article in English | MEDLINE | ID: mdl-15267120

ABSTRACT

Antifungal agents have greatly contributed to the improvement of public health. Nevertheless, antifungal resistant pathogens have increased during the past decade, becoming a serious concern. Candida albicans has been the most extensively studied pathogen in antifungal resistance because of their morbidity and mortality associated with infections in immunocompromised patients. This review describes the antifungal mechanims of the azole fluconazole widely used for the prophylaxis and treatment of candidal infections. The specific molecular pathways occurring in fluconazole-resistance of C. albicans and some issues about new antifungal agents are also discussed.


Subject(s)
Candida albicans/drug effects , Drug Resistance, Fungal/drug effects , Fluconazole/pharmacology , Animals , Candida albicans/genetics , Candidiasis/drug therapy , Candidiasis/prevention & control , Drug Resistance, Fungal/genetics , Fluconazole/therapeutic use , Gene Expression , Humans
16.
Int Immunopharmacol ; 3(8): 1169-76, 2003 Aug.
Article in English | MEDLINE | ID: mdl-12860172

ABSTRACT

Treatment of chronic hepatitis B and C viruses (HBV and HCV) is still disappointing, and both are the major causes of liver cirrhosis and hepatocarcinoma. Interferon and lamivudine are the registered drugs for chronic HBV but are scarcely effective on HBeAg-negative patients, and resistance due to virus mutation is the rule with lamivudine. Interferon and ribavirine represent the standard treatment for chronic HCV but less than the half of the infected population is eligible for this treatment and less of the half of treated patients will experience a sustained response. No single new drug to date has shown the potential to overcome this dismal picture. Combined strategies are thus the currently most available approach to improve the response rate of chronic HBV and HCV infection, with a subsequent decrease in the number of patients developing hepatocellular carcinoma (HCC). Combination of thymosin alpha 1 with interferon or antiviral agents is currently the most promising option, but nontoxic immunomodulants, such as oral MIMP, should be explored. This review focuses on the difficulties with current therapy and the rationale for use of combination therapy with thymosin alpha 1 for both HBV and HCV therapies.


Subject(s)
Carcinoma, Hepatocellular/prevention & control , Hepatitis, Viral, Human/drug therapy , Liver Neoplasms/prevention & control , Thymosin/analogs & derivatives , Adjuvants, Immunologic/therapeutic use , Antiviral Agents/therapeutic use , Clinical Trials as Topic , Drug Therapy, Combination , Hepatitis B, Chronic/complications , Hepatitis B, Chronic/drug therapy , Hepatitis B, Chronic/immunology , Hepatitis C, Chronic/complications , Hepatitis C, Chronic/drug therapy , Hepatitis C, Chronic/immunology , Hepatitis, Viral, Human/complications , Hepatitis, Viral, Human/immunology , Humans , Thymalfasin , Thymosin/therapeutic use
17.
J Med Chem ; 44(26): 4554-62, 2001 Dec 20.
Article in English | MEDLINE | ID: mdl-11741474

ABSTRACT

Several new 6-oxiranyl-, 6-oxiranylmethyluracils, and pyrimidinone derivatives, synthesized by lithiation-alkylation sequence of 1,3,6-trimethyluracil, 1,3-dimethyl-6-chloromethyluracil, and 2-alkoxy-6-methyl-4(3H)-pyrimidinones, showed a potent and selective antiviral activity against Sendai virus (SV) replication. To gain insight into the structural features required for SV inhibition activity, the new compounds were submitted to a pharmacophore generation procedure using the program Catalyst. The resulting pharmacophore model showed high correlation and predictive power. It also rationalized the relationships between structural properties and biological data of these inhibitors of SV replication.


Subject(s)
Antiviral Agents/chemical synthesis , Pyrimidinones/chemical synthesis , Sendai virus/drug effects , Uracil/analogs & derivatives , Uracil/chemical synthesis , Uridine/analogs & derivatives , Uridine/chemical synthesis , Animals , Antiviral Agents/chemistry , Antiviral Agents/pharmacology , Cell Line , Dogs , Models, Molecular , Molecular Conformation , Pyrimidinones/chemistry , Pyrimidinones/pharmacology , Stereoisomerism , Structure-Activity Relationship , Uracil/chemistry , Uracil/pharmacology , Uridine/chemistry , Uridine/pharmacology
18.
J Biol Regul Homeost Agents ; 15(3): 272-6, 2001.
Article in English | MEDLINE | ID: mdl-11693436

ABSTRACT

The replication of Human Immunodeficiency Virus (HIV) in cells of macrophage lineage represents a key pathogenetic event of the neurological damages typically found during the course of this disease. Macrophages are persistently infected cells and thus not susceptible to the cytophatic effect typical of infected activated CD4-lymphocytes. The resistance of macrophages to HIV infection is at least in part mediated by the autocrine production of the nerve growth factor (NGF), a neurokine able to sustain the survival of some cells of bone marrow origin, including monocyte-derived macrophages. This anti-apoptotic effect of NGF in HIV-infected macrophages can be even more relevant at the central nervous system level, where many cells are able to physiologically produce NGF, thus further increasing the survival of macrophages infected by HIV, and enhancing the damages that these cells may induce upon bystander neurons. The proapoptotic effect of soluble factors released by HIV-infected macrophages may heavily affect the survival and functions also of astrocytes, that in turn become unable to sustain neuronal homeostasis. Taken together, this information supports the importance of therapeutic attempts aimed at attacking virus replication in infected macrophages and/or to selectively eliminate these chronically infected and persistently virus-producing cells.


Subject(s)
HIV/growth & development , Macrophages/virology , AIDS Dementia Complex/virology , Astrocytes/physiology , HIV/pathogenicity , HIV Infections/drug therapy , HIV Infections/virology , Homeostasis , Humans , Macrophages/physiology , Nerve Growth Factor/physiology , Neurons/pathology , Virus Replication
19.
20.
J Biol Chem ; 276(42): 39027-36, 2001 Oct 19.
Article in English | MEDLINE | ID: mdl-11495898

ABSTRACT

Survival of memory B lymphocytes is tightly linked to the integrity of the Bcl-2 protein and is regulated by a nerve growth factor (NGF) autocrine circuit. In factor-starved memory B cells, the addition of exogenous NGF promptly induced p38 mitogen-activated protein kinase (MAPK), but not c-Jun N-terminal kinase (JNK), dephosphorylation. Conversely, withdrawal of endogenous NGF was followed by p38 MAPK activation and translocation onto mitochondria, whereby it combined with and phosphorylated Bcl-2, as assessed by co-immunoprecipitation and kinase assays in vivo and in vitro. Mitochondria isolated from human memory B cells, then exposed to recombinant p38 MAPK, released cytochrome c, as did mitochondria from Bcl-2-negative MDCK cells loaded with recombinant Bcl-2. Apoptosis induced by NGF neutralization could be blocked by the specific p38 MAPK inhibitor SB203580 or by Bcl-2 mutations in Ser-87 or Thr-56. These data demonstrate that the molecular mechanisms underlying the survival factor function of NGF critically rely upon the continuous inactivation of p38 MAPK, a Bcl-2-modifying enzyme.


Subject(s)
Apoptosis , B-Lymphocytes/pathology , Cytochrome c Group/metabolism , JNK Mitogen-Activated Protein Kinases , Mitogen-Activated Protein Kinases/antagonists & inhibitors , Nerve Growth Factor/metabolism , Nerve Growth Factor/physiology , Proto-Oncogene Proteins c-bcl-2/metabolism , Animals , Cell Nucleus/metabolism , Cells, Cultured , Cytosol/metabolism , DNA Fragmentation , Enzyme Inhibitors/pharmacology , Humans , Imidazoles/pharmacology , Immunologic Memory , MAP Kinase Kinase 4 , Microscopy, Fluorescence , Mitochondria/metabolism , Mitogen-Activated Protein Kinase Kinases/metabolism , Mitogen-Activated Protein Kinases/metabolism , Phosphorylation , Precipitin Tests , Protein Binding , Protein Transport , Pyridines/pharmacology , Rats , Recombinant Proteins/metabolism , Serine/chemistry , Threonine/chemistry , Time Factors , p38 Mitogen-Activated Protein Kinases
SELECTION OF CITATIONS
SEARCH DETAIL
...